LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Manipulating the Ubiquitination Process May Overcome Glioblastoma Resistance

By LabMedica International staff writers
Posted on 09 Feb 2012
Print article
A complex molecular pathway protects glioblastoma, an aggressive and lethal brain cancer, from treatment based on drugs that target the TNF (tumor necrosis factor)-related apoptosis-inducing ligand (TRAIL) apoptotic pathway.

The TRAIL apoptotic pathway has emerged as a therapeutic target for the treatment of cancer. However, clinical trials have proven that the vast majority of human cancers are resistant to this approach. In a study seeking ways to overcome this resistance, investigators at Emory University (Philadelphia, PA, USA) worked with tumor-initiating cells isolated from glioblastomas surgically removed from patients.

They reported in the January 24, 2012 online edition of the journal Cancer Discovery that A20 E3 (tumor necrosis factor, alpha-induced protein 3 or TNFAIP3) ligase was highly expressed in these cells along with receptor interacting protein 1 (RIP1), and the apoptotic protein caspase-8. Together, these proteins formed a potent signaling complex.

When TRAIL interacted with this complex, the A20 E3 ligase triggered ubiquitination and destruction of RIP1, which interfered with activation of caspase-8 and prevented caspase-8-initiated apoptosis.

These results identify A20 E3 ligase as a therapeutic target whose inhibition can overcome TRAIL resistance in glioblastoma. “Scientists in this field have been hoping to treat this cancer with this new type of apoptosis pathway-targeted therapeutic drug, and this new information may provide a path forward,” said senior author Dr. Chunhai Hao, professor of neuropathology at Emory University.

“Previous research in this area has been unable to overcome the obstacle created by resistance,” said Dr. Hao. “This research shows one of the mechanisms for how we can manipulate the ubiquitination process to overcome the resistance to the apoptosis-targeted cancer therapies. Understanding the mechanisms of resistance is vital to developing therapies going forward.”

Related Links:
Emory University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more